ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Sorafenib is a multikinase inhibitor used in cancer therapy, affecting proliferation, migration, and invasion.
• While known to inhibit Raf, VEGFR, and PDGFR, its precise link to the EGF signaling pathway remains unclear.
• Understanding Sorafenib's molecular targets is crucial for optimizing cancer treatment.

Purpose of the Study:

• To identify the molecular mechanism linking Sorafenib to the EGF signaling pathway.
• To investigate the MEK5/ERK5 signaling pathway as a novel target of Sorafenib.
• To elucidate how Sorafenib affects EGF-mediated biological responses.

Main Methods:

• In silico, chemical, and genetic approaches were used.
• Experiments were conducted in HeLa, U2OS, A549, and HEK293T cell lines.
• MEK5-dependent phosphorylation of ERK5 and its downstream transcriptional activation were analyzed.

Main Results:

• The MEK5/ERK5 signaling pathway was identified as a novel target of Sorafenib.
• Sorafenib was shown to inhibit MEK5-dependent phosphorylation of ERK5 (Ser218/Tyr220).
• Sorafenib's effects on EGF-induced cell cycle progression and migration are mediated via the ERK5 pathway.

Conclusions:

• The MEK5/ERK5 pathway is a newly identified molecular target of Sorafenib.
• This study provides novel mechanistic insights into Sorafenib's anti-tumor activity.
• Targeting the ERK5 pathway may offer new therapeutic strategies in cancer treatment.